Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia.
Kluger
Nicolas
N
Cartron
Guillaume
G
Bessis
Didier
D
Guillot
Bernard
B
Girard
Céline
C
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002481:Cellulitis / Q000139:chemically induced* / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D041041:Citrobacter koseri / Q000302:isolation & purification*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008875:Middle Aged; D012867:Skin / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C527517:ofatumumab